SecBot SecBot

OPTH

Optimi Health Corp.
Nasdaq· Pharmaceutical Preparations· Inc. A1· CIK 0002027329 Biotech & Drug Discovery
$3.25 −0.03 (−0.91%)
Oct 23 4:00 PM ET · prev $3.28
Market cap
$18.8M
Nano cap
Since first trade
−46.5%
from $6.08 · May 20
30 days
−33.7%
from $4.90
Range since listing
$3.17–6.08
−47% from high · low Oct 14
Avg volume 20D
27.8K
shares / day
Short interest
29.5K
≈0.5% of shares · +43.7%
Days to cover
1.0
at average volume
Filing reports
20
analyzed by SecBot
SecBot read MIXED 14 reports · 90 days
Balance 3 bearish · 3 bullish · 8 neutral oldest → newest, height = score
Avg score ·High conf. 8/14
Strongest NEUTRAL Optimi Health Corp. announced completion of an MDMA production batch to supply a proposed Canadian Phase 3…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • Short sellersBUILDING

    Short interest +43.7% to 29.5K shares. 1.0 days to cover, ≈0.5% of shares.

  • TrendDOWNTREND

    27% below its 50-day average.

  • SocialQUIET

    No Reddit mentions this week. Last mention Sep 28.

Who's buying

13F
Top holderSharesValue
UBS Group AG5,872$29.9K
ROYAL BANK OF CANADA1,964$10.0K
NATIONAL BANK OF CANADA /FI/598$3.1K
TD Waterhouse Canada Inc.333$1.7K
Mariner, LLC122,250$837.00
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO136$692.00
Arax Advisory Partners50$254.00

Quarterly 13F filings are due 45 days after each quarter ends.

Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 26, 2026 SEC
🔒 Fresh report (last 24h) — subscribers only
Oct 20, 2026 SEC
Optimi Health Corp. announced completion of an MDMA production batch to supply a proposed Canadian Phase 3 PTSD trial…
6-K — Impact 4/10
Oct 7, 2026 SEC
Optimi Health Corp. announced it will present a corporate overview and hold one-on-one investor meetings at the…
6-K — Impact 2/10
Sep 16, 2026 Other
Optimi Health Expands Clinical Program with Phase 3 Trial Evaluating MDMA-Assisted Therapy for Post-Traumatic Stress Disorder
Health Canada-authorized trial to evaluate efficacy and safety of two sessions of MDMA-assisted ther
May 29, 2026 Press
Optimi Health acknowledged the TGA's final recommendations expanding Australia's Authorized Prescriber scheme for…
Impact 6/10

Earnings setup

Estimates

Revision history: 🔒 Fresh data — subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data — subscribers only
Next Q🔒 Fresh data — subscribers only
Current FY🔒 Fresh data — subscribers only
Next FY🔒 Fresh data — subscribers only
Reddit
Recent posts
r/pennystocks Bullish 28d ago
OPTH (Optimi Health) – DD on a psychedelic drug manufacturer that’s already generating revenue
1 upvotes · 1 comments
All social signals and their track records

Short side

FINRA· Sep 30, 2026
29,452
shares short
+43.7%
vs prior settlement
1.0
days to cover
≈0.5%
of shares outstanding
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Sep 16, 2026
Press release
Optimi Health Expands Clinical Program with Phase 3 Trial Evaluating MDMA-Assisted Therapy for Post-Traumatic Stress Disorder
Health Canada-authorized trial to evaluate efficacy and safety of two sessions of MDMA-assisted therapy in up to 100 veterans and frontline workers…
Aug 14, 2026
Press release
Optimi Health Establishes Discretionary Equity Facility
VANCOUVER, British Columbia, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) (the “ Company ” or “…
Jun 29, 2026
Press release
Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression
Optimi’s 5mg psilocybin capsules are prescribed in Australia for treatment-resistant depression. The export marks Optimi’s third commercial shipment…
Jun 10, 2026
Press release
Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial
The shipment of naturally derived psilocybin, comprising both biomass and 5mg capsules, supports a planned Phase 2 clinical trial in the United…
Jun 2, 2026
Announcement
Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia
Optimi’s 5mg psilocybin capsules are prescribed commercially for treatment-resistant depression in Australia, with additional product from the run…

SecBot reports

20 filings · 1 press releases · 5 bullish · 3 bearish · 12 neutral
All OPTH filing & press-release reports (24)